Consensus Cara Therapeutics, Inc. Berne S.E.

Equities

69C

US1407551092

Delayed Berne S.E. Other stock markets			5-day change	1st Jan Change
- ^CHF	-.--%		-.--%	-.--%

06-20	Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	MT
06-18	Cara Therapeutics to Idle 70% Workforce, Explore Alternatives After Scrapping Notalgia Paresthetica Program	MT

Evolution of the average Target Price on Cara Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

94c96c3a34cf835259609169f8c.WlI_3LlPgjKZVKLNwxE03OIo_v_aQS0cul5y6VIoqZU.az8Hsfs8wHDeJ-eMpFxWl5h3lp2bcB9u8DIQsx9Y8ft3F2-z0DzuW9Ys6w~8b1442cb06f0f3ffc31301772ad03d1f

Analyst Recommendations on Cara Therapeutics, Inc.

Needham Downgrades Cara Therapeutics to Hold From Buy	06-13	MT
HC Wainwright Downgrades Cara Therapeutics to Neutral From Buy	06-13	MT
Stifel Downgrades Cara Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $6	06-13	MT
Canaccord Genuity Downgrades Cara Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10	06-13	MT
Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating	03-06	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $2.50 From $7, Keeps Buy Rating	12-19	MT
Needham Adjusts Price Target on Cara Therapeutics to $6 From $22, Maintains Buy Rating	12-18	MT
Piper Sandler Downgrades Cara Therapeutics to Neutral From Overweight, Cuts Price Target to $1 From $12	11-14	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $7 From $15, Keeps Buy Rating	23-10-19	MT
HC Wainwright Lowers Price Target on Cara Therapeutics to $15 From $20, Maintains Buy Rating	23-05-16	MT
BofA Securities Adjusts Price Target on Cara Therapeutics to $4 From $6, Maintains Underperform Rating	23-05-16	MT
BofA Securities Downgrades Cara Therapeutics to Underperform From Neutral, Cuts PT to $6 From $13 on Lower Peak Sales Forecast of Drug	23-03-08	MT
BofA Downgrades Cara Therapeutics to Underperform From Neutral, Adjusts Price Target to $6 From $13	23-03-08	MT
Canaccord Genuity Adjusts Price Target on Cara Therapeutics to $25 From $29, Maintains Buy Rating	23-03-07	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $20 From $25, Keeps Buy Rating	23-03-07	MT
Piper Sandler Adjusts Price Target on Cara Therapeutics to $13 From $25, Keeps Overweight Rating	23-03-07	MT
JPMorgan Adjusts Price Target on Cara Therapeutics to $16 From $19, Maintains Overweight Rating	23-03-07	MT
Needham Cuts Price Target on Cara Therapeutics to $22 From $26, Maintains Buy Rating	23-03-07	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $25 From $30, Maintains Buy Rating	23-02-14	MT
Canaccord Genuity Adjusts Cara Therapeutics' Price Target to $29 from $33, Keeps Buy Rating	22-03-14	MT
HC Wainwright Adjusts Cara Therapeutics' Price Target to $30 from $35, Keeps Buy Rating	22-03-14	MT
JPMorgan Raises Cara Therapeutics to Overweight From Neutral, Price Target to $20 From $17	22-03-08	MT
CARA THERAPEUTICS : HC Wainwright Adjusts Price Target on Cara Therapeutics to $35 From $33, Maintains Buy Rating	21-08-24	MT
CARA THERAPEUTICS : JPMorgan Starts Cara Therapeutics at Neutral With $16 Price Target	21-08-03	MT
CARA THERAPEUTICS : Needham & Co Adjusts Cara Therapeutics PT to $26 From $35, Maintains Buy Rating	21-04-29	MT